Results 11 to 20 of about 871,767 (407)

TYROSINE KINASE INHIBITORS AND INTERFERON

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for
Maria Dimou, Panagiotis Panagiotidis
doaj   +4 more sources

TYROSINE KINASE INHIBITORS AND PREGNANCY

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate.  The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of ...
Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti   +3 more
doaj   +5 more sources

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia [PDF]

Haematologica, 2015
This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Eolia Brissot, Myriam Labopin, Marielle M. Beckers, Gérard Socié, Alessandro Rambaldi, Liisa Volin, Jürgen Finke, Stig Lenhoff, Nicolaus Kröger, Gert J. Ossenkoppele, Charles F. Craddock, Ibrahim Yakoub-Agha, Günhan Gürman, Nigel H. Russell, Mahmoud Aljurf, Michael N. Potter, Armon Nagler, Oliver Ottmann, Jan J. Cornelissen, Jordi Esteve, Mohamad Mohty   +20 more
doaj   +3 more sources

Ocular Toxicity of Tyrosine Kinase Inhibitors. [PDF]

Oncology Nursing Forum, 2016
To review common tyrosine kinase inhibitors, as well as their ocular side effects and management.
.A comprehensive literature search was conducted using CINAHL®, PubMed, and Cochrane databases for articles published since 2004 with the following search terms.Tyrosine kinase inhibitors can cause significant eye toxicity.
M. Davis
semanticscholar   +4 more sources

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Haematologica, 2019
There are no validated molecular biomarkers to identify newly-diagnosed individuals with chronic-phase chronic myeloid leukemia likely to respond poorly to imatinib and who might benefit from first-line treatment with a more potent second-generation ...
Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, Gareth Gerrard, Edward Curry, Richard Szydlo, Mary Alikian, Hui En Foong, Zacharoula Nikolakopoulou, Sandra Loaiza, Jamshid S. Khorashad, Dragana Milojkovic, Danilo Perrotti, Robert Peter Gale, Letizia Foroni, Jane F. Apperley   +15 more
doaj   +2 more sources

Second-generation inhibitors of Bruton tyrosine kinase

Journal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu, Christina Liu, Stella T. Tsui, Delong Liu   +3 more
doaj   +2 more sources

Bruton tyrosine kinase inhibitors for multiple sclerosis

Nature Reviews Neurology, 2023
Bruton tyrosine kinase inhibitors are an emerging treatment for multiple sclerosis. Krämer et al. consider the evidence that central nervous system-penetrant Bruton tyrosine kinase inhibitors might target both peripheral immune cells and ...
J. Krämer, A. Bar-Or, T. Turner, H. Wiendl   +3 more
semanticscholar   +1 more source

Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.

New England Journal of Medicine, 2022
BACKGROUND Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL).
E. Wang, Xiaoli Mi, Meghan C. Thompson, S. Montoya, R. Notti, Jumana Afaghani, B. Durham, A. Penson, Matthew T. Witkowski, Sydney X Lu, J. Bourcier, Simon J. Hogg, C. Erickson, Daniel Cui, Hana Cho, Michael Singer, T. Totiger, S. Chaudhry, M. Geyer, Alvaro J Alencar, A. Linley, M. Palomba, Catherine C Coombs, Jae H. Park, A. Zelenetz, L. Roeker, M. Rosendahl, D. E. Tsai, K. Ebata, B. Brandhuber, D. Hyman, I. Aifantis, A. Mato, Justin Taylor, O. Abdel-Wahab   +34 more
semanticscholar   +1 more source

Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report

Cancer Treatment and Research Communications, 2021
Tyrosine kinase inhibitors are the first-line treatment for Anaplastic Lymphoma Kinase-positive lung adenocarcinomas. However, chemotherapy is still an option in patients who are unresponsive or intolerant of tyrosine kinase inhibitors.
Oranus Mohammadi, Kayla Haines, Mohammad Jahanzeb   +2 more
doaj   +1 more source

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

npj Breast Cancer, 2021
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib ...
I. Schlam, S. Swain
semanticscholar   +1 more source